Notable insider buying and selling activity across public companies.
Tracking and analysis of reported insider transactions, including executive and director buying or selling. Insider activity can offer insight into internal confidence, valuation perceptions, and potential inflection points.
13,303 total articles
Murray Stahl, President and Co-Portfolio Manager of RENN Fund, Inc. (RCG), reported acquiring 1,134 shares of the fund's common stock on March 10, 2026, at $2.93 per share, for a total of $3,322. The filing lists purchases executed through several related entities. RCG was trading at $3.06 at the time of reporting and is near a 52-week high per Inv…
NXG NextGen Infrastructure Income Fund reported a director purchase and an at-the-market share offering in separate disclosures. CEO and President John M. Musgrave bought 400 common shares on March 10, 2026, for $52.00 each, while the fund put in place a distribution agreement enabling the sale of up to 1,600,000 common shares through Foreside Fund…
Indivior Pharmaceuticals director Kingsley Stuart A. bought 940 shares on March 6, 2026, at $31.865 per share for a total of $29,953. The stock trades at $33.73 following a strong set of fourth-quarter and full-year 2025 results that outperformed expectations on both EPS and revenue. Independent analysis flags the stock as fairly valued, even as th…
Lawrence B. Seidman, a director of Bankwell Financial Group, Inc. (NASDAQ: BWFG), acquired $471,080 worth of common stock on March 10, 2026. The purchases, executed at prices between $46.93 and $47.06 per share, come after the shares delivered a 64.61% return over the past year. The company also reported stronger-than-expected fourth-quarter 2025 r…
Japan Post Holdings Co., Ltd., a roughly ten-percent owner of Aflac Inc. (NYSE: AFL), sold 17,300 Aflac common shares on March 9, 2026, in transactions that totaled $1,896,481. The trade, disclosed on a Form 4 filing with the SEC, came at prices closely aligned with Aflac's prevailing market level. The move follows Aflac's mixed fourth-quarter 2025…
ResMed Chairman and CEO Michael J. Farrell sold 4,991 shares on March 9, 2026, for roughly $1.25 million while exercising options to acquire an identical number of shares at a significantly lower strike price. The moves were carried out under a Rule 10b5-1 trading plan adopted in October 2024. The company recently posted better-than-expected earnin…
Director Ryan Barbara acquired 31 shares of Indivior Pharmaceuticals, a move that raises his direct stake to 5,716 shares. The purchase comes while INDV shares trade close to their InvestingPro Fair Value and following a fourth-quarter and full-year 2025 earnings report that beat consensus on both EPS and revenue.
A director at Solventum Corp reported a purchase of 1,475 shares on March 10, 2026, according to a filed Form 4. The acquisition, priced at $68.03 per share and totaling roughly $100,344, increases the director's direct holdings to 5,039 shares. The transaction comes amid mixed quarterly results and an analyst reiteration of an Overweight rating.
Jared Isaacman, a 10% owner of Shift4 Payments, purchased 43,827 shares of the company’s Class A common stock on March 10, 2026, spending $2,004,879 across transactions priced between $45.7245 and $45.7661. The buy increases his direct stake while the stock trades close to its 52-week low and follows recent corporate moves including the acquisition…
SBC Medical Group Holdings Inc. Chairman and CEO Aikawa Yoshiyuki sold 4,422,900 shares on March 6, 2026, for $2.12 per share, totaling $9,376,548. The company has simultaneously advanced capital-marketing flexibility with a $50 million shelf registration and a $20 million buyback program, made a minority investment in OrangeTwist to enter the U.S.…
Sheri Pearce, Senior Vice President of Accounting and Chief Accounting Officer at Antero Midstream Corp (AM), sold 14,000 shares for $318,640 on March 10, 2026, shortly after receiving a restricted stock unit grant. The transactions occurred while AM shares trade close to their 52-week peak and following the company’s mixed fourth-quarter 2025 resu…
Hinge Health Executive Chairman and Co-Founder Gabriel M.I. Mecklenburg sold 166,666 Class A shares for about $7.5 million on March 6, 2026, while converting 166,666 Class B shares to Class A at no cost. The transactions occurred at prices close to the prevailing market level and follow the company's Q4 2025 results, which drew a range of analyst r…
Richard H. Fearon, a member of Waters Corp's board, bought 1,000 shares of the company on March 6, 2026, spending $306,340 on the transactions. The purchases were executed across multiple trades at prices between $305.84 and $306.49 per share, leaving Fearon with direct ownership of 3,302 shares. The insider activity comes as Waters' stock is down …
Shake Shack Chief Operating Officer Stephanie Ann Sentell sold 225 shares of the company’s Class A common stock on March 6, 2026, through a pre-established trading plan. The transaction totaled $21,060, reducing her direct stake to 15,342 shares. The company recently reported Q4 2025 results and drew higher price targets and fresh coverage from sev…
Lee Enterprises Director David Henry Hoffmann purchased 74,600 shares of the company across three transactions in March 2026, spending roughly $683,072. The acquisitions increase his direct stake to 11,183,049 shares, with an additional 618,900 held indirectly. The transactions coincide with a quarter that delivered substantial digital revenue gain…
Foxx Development Holdings Inc. (NASDAQ: FOXX) reported that Chief Technology Officer James Liao sold 9,716 shares of common stock on February 19, 2026, at $4.61 per share, resulting in proceeds of $44,790. The filing shows Liao now holds zero shares directly. The company also disclosed the appointment of Michelle Jie Shen to its board, an indemnifi…
Thomas F. Kissinger, senior executive vice president, general counsel and secretary of Marcus Corporation, sold 25,000 shares of the company's common stock on March 6, 2026, for $433,000. Post-sale, Kissinger remains a significant holder of Marcus Corp (NYSE: MCS) common stock and controls a sizeable pool of unexercised stock options. The company r…
Greg McWilliams, Chief Policy Officer and Vice President of Five Point Holdings (FPH), sold a tranche of Class A common stock early in March 2026 while also acquiring shares via the exercise of restricted share units. The company reported record net income for Q4 2025 and a full-year profit that exceeded internal guidance, with substantial cash res…
Acumen Pharmaceuticals Chief Legal Officer Derek M. Meisner completed an automatic sale of 2,090 shares on March 6, 2026, and on the same date exercised options to acquire 2,090 shares. The transactions occurred as ABOS shares trade near a 52-week high and reflect holdings that include a substantial direct stake and outstanding options.
First Solar General Counsel and Secretary Jason E. Dymbort sold 1,305 shares on March 9, 2026 for roughly $248,419, following an option exercise and multiple restricted stock unit vestings on March 6, 2026. The transactions leave him with 18,376 directly held shares as the company navigates downward revisions and multiple analyst downgrades tied to…
Patrick James Buehler, Chief Product Officer of First Solar, sold 697 shares on March 9, 2026 for $132,680 while earlier exercising options and receiving new restricted stock units. The transactions coincide with a stock price trading at $197.80, a 24% year-to-date decline, and a string of analyst downgrades after fourth-quarter results and 2026 re…
Michael Koralewski, First Solar’s Chief Supply Chain Officer, sold 756 shares on March 9, 2026 for $190.36 apiece, amounting to $143,912, according to a Form 4 filing. The filing also shows Koralewski received 1,854 shares on March 6, 2026 upon vesting of restricted stock units, with no payment required. Several research firms have downgraded or tr…
First Solar Chief Technology Officer Markus Gloeckler sold 1,325 shares of common stock on March 9, 2026, for $252,227. The transaction occurs amid a stock price that is down year-to-date and following a fourth-quarter earnings miss and below-street 2026 revenue guidance that has led several firms to lower ratings and targets.
Callan JMB Inc. reported that Chief Medical Officer Croyle David J purchased 14,805 shares of common stock on March 6, 2026, at $1.762 per share for a total of $26,086. The transaction, filed on a Form 4 with the Securities and Exchange Commission, increased Croyle’s holdings to 789,805 shares and was executed indirectly through a Rollover IRA. The…
Director Mannes Joseph R. sold 1,500 shares of DXP Enterprises Inc. on March 9, 2026, for $137.95 per share, realizing proceeds of $206,924 and leaving him with 13,964 shares. The transaction occurred while DXPE stock trades near $140.12 after an 83 percent one-year gain. Recent company results show a revenue beat and double-digit top-line growth f…
